



## Controversial Pathogen: *Blastocystis hominis* Prevalence from Patients Attending a Tertiary Care Hospital Lucknow

Authors

Taiyaba<sup>1\*</sup>, Malay Banerjee<sup>2</sup>, Farhat Tahira<sup>3</sup>, Mohammad Azam<sup>4</sup>,  
Devendra K Niranjana<sup>5</sup>

<sup>1\*</sup>Demonstrator, Dept of Microbiology, Career Institute of Medical Sciences and Hospital Lucknow

<sup>2</sup>Professor, Dept of Microbiology, Career Institute of Medical Sciences and Hospital Lucknow

<sup>3</sup>Associate Professor, Dept of Microbiology, Career Institute of Medical Sciences and Hospital Lucknow

<sup>4</sup>Professor & CMS, Dept of Community Medicine, Career Institute of Medical Sciences and Hospital Lucknow

<sup>5</sup>Assistant Professor, Dept of Microbiology, Career Institute of Medical Sciences and Hospital Lucknow

Corresponding Author

\*Miss. Taiyaba

Demonstrator, Career Institute of Medical Sciences and Hospital Lucknow

Email: [sabakhansktk91@gmail.com](mailto:sabakhansktk91@gmail.com)

### ABSTRACT

*Blastocystis hominis* (*B. hominis*) is one of the most common enteric parasite and a highly controversial protozoan parasite regarding its pathogenicity. It has been variably regarded as a commensal and as a pathogen. The aim of this study was to determine the prevalence of *B. hominis* in relation to sex and age. The purpose of this study was to get a clear idea about the existence of *B. hominis* in symptomatic patients and their pathogenic effect in absence of other known pathogen. The present study was conducted in the Department of Microbiology of a tertiary care Hospital in Lucknow, India. Samples were collected after taking informed consent. A total of 502 stool samples were examined microscopically. Out of all the samples examined 97 samples were found to be positive for at least one parasite. Among them *B. hominis* was found in fecal material of 17 patients (17.5%). In the present study common symptoms associated with *B. hominis* infection were abdominal pain (100 %), diarrhea (76.4 %), Nausea (64.7 %), Loss of weight (41.1%), Vomiting (23.5 %), Constipation (23.5 %). All the 17(17.5%) patients were treated with metronidazole 250 to 500 mg BID for 5-7 days because of symptoms and the presence of *B. hominis* stool specimens. After 5-7 days of treatment, all patients became asymptomatic with stools negative for *B. hominis* on follow-up examinations.

**KEYWORDS:** *B. hominis* Pathogenicity, Controversial Protozoan Parasite.

### INTRODUCTION

*B. hominis* is a unicellular protozoan and one of the most common parasite found in the human intestinal tract. *B. hominis* was first described 100 years ago but surprisingly little is known about its pathogenicity [1-5]. Pathogenic potential of *B.*

*hominis* in human enteric disease had been reported in the older literature [6-9] and most of the textbooks described it as a commensal [10-12]. *B. hominis* is now getting acceptance as an agent of human intestinal disease [13-14]. Infection with *B. hominis* has a worldwide distribution and occurs

in both children and adults. In developing countries, *B. hominis* has a higher prevalence (30-50%) in comparison with developed countries (1.5-10%). The high prevalence in developing countries is related to poor hygiene, and consumption of contaminated food or water<sup>[15-16]</sup>.

*B. hominis* is accepted as agents of tourist diarrhea and the most common symptoms associated with *B. hominis* infection include diarrhoea, abdominal pain and vomiting. It causes persistent or recurrent diarrhoea in patients with AIDS and other immunodeficiencies<sup>[17]</sup>.

## MATERIALS AND METHODS

Prospective study was carried out in Microbiology laboratory of Integral Institute of Medical Sciences and Research, Dasauli, Kursi road, Lucknow. Study period was 6 months from January 2015 – June 2015. The study was

approved by the Institutional Ethics Committee. A total of 502 samples were examined for the presence of intestinal parasites. None of the patients were immunocompromised.


The fecal specimens were grossly examined for stool color, consistency, mucus, blood and visible parasites. All specimens were subsequently sedimented by the formol-ether and floated by the saturated salt solution. All the specimens were subjected to microscopic examination with Lugol's and Iodine wet mount before and after concentration methods. Specimens also subjected to Modified Zeil Neelsen staining to look for coccidian parasites.

## RESULTS

A total of 97 (19.32 %) samples revealed presence of parasites. Out of which, 17 (17.5%) samples were found to be positive for *B. hominis* only.


**Table 1: Prevalence of *Blastocystis hominis***

No. of Samples n	Total Parasite Prevalence n (%)	<i>B. hominis</i> Prevalence n (%)
502	97(19.32%)	17(17.5)



**Table 2: Gender-wise prevalence of *Blastocystis hominis***

Name of parasites	Number of parasites (%)	Male n (%)	Female n (%)
<i>Blastocystis hominis</i>	17 (17.5)	15(88.2)	2(11.7)



**Table 3. Distribution of *Blastocystis hominis* in Males of different age group**

PARASITE	0-6 mnth	7mnth-5yrs	6-20yrs	21-40 yrs	41-60yrs	>60 yrs
<i>B.hominis</i>	0	2	4	3	6	0

Among the males of different age group *Blastocystis hominis* was most frequently found in the age group of 41-60 years.

**Table 4. Distribution of *Blastocystis hominis* in Females of different age group**

PARASITE	0-6 mnth	7mnth-5yrs	6-20yrs	21-40 yrs	41-60yrs	>60 yrs
<i>B.hominis</i>	0	0	1	1	0	0

**Table 5. Frequency of symptoms in patients with *B. hominis* detected in stool examination**

Clinical Feature	Patients Number (17)	%
Abdominal pain	17	100
Diarrhoea	13	76.4
Nausea	11	64.7
Loss of weight	7	41.1
Constipation	4	23.5
Vomiting	4	23.5

In the present study out of 17 patients all the patients have abdominal pain (100%) with diarrhoea (76.4%) and constipation (64.6%). Other symptoms and their frequency rates are given in table no. 5.

**Table 6. Clinical response rates after treatment with metronidazole**

Clinical Feature	Follow-up Patients Number	Post therapeutic Clinical response %
Nausea	11	100
Diarrhoea	13	96.5
Abdominal pain	17	92.3
Vomiting	4	92.1
Constipation	4	52
Loss of weight	7	0

A second stool specimen was obtained from all the 17 patients after metronidazole therapy. The consecutive parasitological investigation revealed no intestinal protozoa in *B. hominis* positive stool specimens. Intestinal symptoms: abdominal pain (100%) with diarrhoea (76.4%) and constipation (64.6%) improved in *B. hominis* detected patients. Clinical symptoms Nausea and Vomiting disappeared in (100%) and (92.1 %) patients respectively.

## DISCUSSION:

There is still much debate about the pathogenicity of *B. hominis* in humans. Though many authors have recognized it as a pathogen <sup>[18-19]</sup>, however, there are still many authors who doubt the ability of *B. hominis* as a pathogen in human <sup>[20-21]</sup>.

In the present study, among the 17 patients in which *B. hominis* was detected, it represented the sole causative parasitic agent. Similarly, studies done by El- Shazly *et. al.* and Selcuk KAYA

*et. al.*, reported 23 and 52 symptomatic patients respectively in which *B. hominis* represented the only causative parasitic agent <sup>[22-23]</sup>.

In the present study *B. hominis* was detected only in symptomatic patients. The most common symptoms were abdominal pain (100%), diarrhoea (76.4%), nausea (64.7 %) and vomiting (23.5%). The studies done by Dogan N and Selcuk Kaya *et. al.*,<sup>[24-23]</sup> showed similar results. Intestinal symptoms: abdominal pain (100%) with diarrhoea

(76.4%) and constipation (64.6%) improved in *B. hominis* detected patients. Clinical symptoms Nausea and Vomiting disappeared in (100%) and (92.1%) patients respectively. All of these symptoms improved after metronidazole therapy so we can put forward this protozoon as possible pathogenic according to the good response to metronidazole therapy in these patients.

In our study, prevalence of *B. hominis* was more in males (88.2%) as compared to that in females (11.7%). whereas a study done by **Husain et al.**, showed higher rate of infection among females in comparison to males<sup>[25]</sup>. Among the males of different age groups, *B. hominis* was most frequently found in the age group of 41-60 years. The clinical literature offers no conclusive evidence as to what constitutes effective treatment for the eradication of *B. hominis*. In the present study, 17 persons who had *B. hominis* as the only finding in their stool examination were administered metronidazole 250 to 500 mg BID for 7 days. All patients became asymptomatic and *B. hominis* was detected in none of the stool samples. Similarly, **Kain et al.**, treated 18 persons with gastrointestinal symptoms alongwith *B. hominis* in the stool with metronidazole (250 to 750 mg TID for 5-10 days). Fourteen (78%) became asymptomatic or had an improvement in their symptoms<sup>[26]</sup>. However, other authors have had less success. Grossman found that only 13% of patients treated with metronidazole had a microbiologic cure<sup>[27]</sup>. **Markell and Udkow** found that metronidazole failed to eradicate *B. hominis*<sup>[28]</sup>.

## CONCLUSION

*B. hominis* parasite infection has been considered nonpathogenic as a commensal organism. However, in immunocompromised cases this parasite proved as pathogenic.

In our study out of 502 cases 17 cases were proved to be positive for *B. hominis*. These cases have various symptoms like Diarrhoea, Abdominal pain, Nausea, Vomiting, Constipation, Loss of weight.

The cases were treated with metronidazole and were found negative for *B. hominis* on subsequent stool examination with improvement in symptoms.

Therefore *B. hominis* seem to be able to reveal various intestinal symptoms and considered as pathogenic organism in humans which must be treated successfully with metronidazole.

## REFERENCES

1. **Zierdt CH**, Blastocystis hominis—past and future. *Clin Microbiol Rev*, 1991(1)61–79.
2. **Zierdt CH, Donnelly CT**, Muller J, Constantopoulos G, Biochemical and ultrastructural study of Blastocystis hominis. *J Clin Microbiol*, 1988(5): 65–970.
3. **Arisue N, Hashimoto T, Yoshikawa H, Nakamura Y, Nakamura G, Nakamura F, Yano TA, Hasegawa M**, Phylogenetic position of Blastocystis hominis and of stramenopiles inferred from multiple molecular sequence data. *J Eukaryot Microbiol*, 2002 (1):42–53.
4. **Tan KS**, New insights on classification, identification, and clinical relevance of Blastocystis spp. *Clin Microbiol Rev*, 2008(4) 39–665.
5. **Silberman JD, Sogin ML, Leipe DD, Clark CG**, Human parasite finds taxonomic home. *Nature* 1996, 380(6573):398.
6. **Barilari, M. J.**, Blastocystis hominis (sic). *Prensa Med. Argent.* 1924(11):54-858.
7. **Caderin C. C.**, El Blastocystis hominis como parasite patogeno del hombre. *Rev. Med. Trop. Parasitol*, 1937(3) 07-213.
8. **Mazza S.**, Frecuenciadel Blastocystis hominis en as deposiciones de diarreicos cronicos y su tratiminto apropiado. *Prensa Med. Argen*, 1922(9)60-463.
9. **SangiorgiG.**, Pathogenicity of Blastocystis hominis. *Pathologica* 1930(22) 73-176.
10. **Kudo, R. R, Charles C**, Protozoology, *Thomas Publisher*, Springfield 1977(3) 1073-1074.

11. **Miller, J. H T**, The protozoa In A. J. Braude, C. E. Davis, and J. Fierer, Infectious diseases and medical microbiology. *The W. B. Saunders Co., Philadelphia*, 1986(6)610-625.
12. **Smith, J. W, and M. J. Bartlett A. Balows and W. J. Hausler**, Diagnostic procedures for bacterial, mycotic and parasitic infections. *American Public Health Association, Washington, D.C* 1981(4) 1153-1174.
13. **Moghaddam DD, Ghadirian E and Azami M**, Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole. *Parasitol Res*, 2005 (4): 273-275
14. **El-Shazly AM, Abdel-Magied AA, El-Beshbishi SN, El- Nahas HA, Fouad MA, Monib MS**, Blastocystis hominis among symptomatic and asymptomatic individuals in Talkha Center, Dakahlia Governorate, Egypt. *J Egypt Soc Parasitol*. 2005(2): 653-66
15. **Tenzel DJ, Boreham PF**. Blastocystis hominis revisited. *Clin Microbiol Rev*. 1996 (9)563–584.
16. **Tan KS**, New insights on classification, identification, and clinical relevance of *Blastocystis spp.* *Clin Microbiol Rev*. 2008 (1):639–665.
17. **Cimerman S, Cimerman B, Lewi DS**, Prevalence of intestinal parasitic infections in patients with acquired immunodeficiency syndrome in Brazil. *Int J Infect Dis*, 1999(4): 203-206.
18. **Andiran N, Acikgoz ZC, Turkay S, Andiran F**, Blastocystis hominis—an emerging and imitating cause of acute abdomen in children. *J Pediatr Surg* 2006, 41(8):1489–1491.
19. **Levy Y, George J, Shoenfeld Y**, Severe Blastocystis hominis in an elderly man. *Journal of Infect* 1996(1):57–59.
20. **Leder K, Hellard ME, Sinclair MI, Fairley CK, Wolfe R**, No correlation between clinical symptoms and Blastocystis hominis in immunocompetent individuals. *J Gastroenterol Hepatol* 2005, 20(9):1390–1394.
21. **Tungtrongchitr A, Manatsathit S, Kositchaiwat C, Ongrotchanakun J, Munkong N, Chinabutr P, Leelakusolvong S, Chaicumpa W**, Blastocystis hominis infection in irritable bowel syndrome patients. *Southeast Asian J Trop Med Public Health* 2004(3):705–710.
22. **El-Shazly AM, Abdel-Magied AA, El-Beshbishi SN, El- Nahas HA, Fouad MA, Monib MS**, Blastocystis hominis among symptomatic and asymptomatic individuals in Talkha Center, Dakahlia Governorate, Egypt. *J Egypt Soc Parasitol*. 2005(2): 653-66.
23. **Selçuk Kaya1, Emel Sesli Çetin1, Buket Cicioğlu Aridoğan1, Salih Arıkan1, Mustafa DEMİRCİ1** Pathogenicity of *Blastocystis hominis*, A Clinical Reevaluation *Türkiye Parazitoloji Dergisi*, 2007 (3): 184-18.
24. **Doğan N**, Prevalance of *Blastocystis hominis* in Bozan region. *Türkiye Parazitol Derg*, 1998(3):247-250.
25. **S. M. Hussain qadri, ghadeer a. Al-okaili, and fouad al-dayel**, Clinical Significance of *Blastocystis hominis*, *journal of clinical microbiology*, 1989 (27) 2407-09
26. **Kain K, Noble MA, Freeman HJ, Barteluk RL**, Epidemiology and clinical features associated with *Blastocystis hominis* infection. *Diagn Microbiol Infect Dis* 1987(8)235-44.
27. **Grossman I, Weiss LM, Simon D, Tanowitz HB, Wittner M**. Blastocystis hominis in hospital employees. *Am J Gastro* 1992(87)729-732
28. **Markell EK, Udkow M**, Blastocystis hominis: Pathogen or fellow traveler? *Am J Trop Med Hyg* 1986(35)1023-1026.